3Abdul Ksiraj, Hussain AR, A1-Rasheed M,et al. Demeth- ylation of TMS1 gene sensitizes thyroid cancer cells to TRAIL-induced apoptosis[J]. J Clin Endocrinol Metab, 2011,96(1) :215-224.
4Xing J,Liu R,Xing M,et al. The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFFV600E inhibitor PLX4032 (RG7024)[J]. Biochem Biophys Res Commun,2011,404(4):958-962.
5Haymart MR, Repplinger DJ, Leverson CE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage[J]. J Clin Endo- crinol Metab, 2008,93 (3) : 809-814.
6Carayon P,Thomas-Morvan C,Castanas E, et al. Human thyroid cancer:membrane thyrotropin binding and adeny- late cyclase activity[J]. J Clin Endocrinol Metab, 1980,51 (4) :915-920.
7Samadi A,Loo P,Mukerji R,et al. A novel HSP90 modu- lator with selective activity against thyroid cancers in vitro[J]. Surgery,2009,146(6) :1196-1207.
8Hoelting T,Coretzki PE, Duh QY. Follicular thyroid cancer cells:a model of metastatic tumor in vitro(review)[J]. Oncol Rep,2001,8(1) :3-8.
9Kebebew E, Klark OH. Differentiated thyroid cancer:" complete" rational approach[J]. World J Surg, 2000,24 (8):942-951.
10Tucker MA, Boice JD Jr, Hoffman DA. Second cancer fol- lowing cutaneous melanoma and cancers of the brain, thy- roid, connective tissue, bone, and eye in Connecticut, 1935-82[J]. Natl Cancer Inst Monogr, 1985,20(68) : 161- 189.
